Clinical TrialMay 13, 2026, 04:07 PM
Vivani Medical on track for SLIM-1 Phase 1 trial mid-2026; $28M cash runway
AI Summary
Vivani Medical, Inc. reported its first-quarter 2026 financial results and provided a business update, confirming the initiation of its SLIM-1™ Phase 1 clinical trial for NPM-139 (a semaglutide implant for weight management) is on track for mid-2026, with top-line results expected by year-end. The company also announced a strong financial position with $28 million in cash and commitments, providing a runway through the first half of 2027. Additionally, Vivani is progressing with its next-generation implant and exploring options for its neuromodulation subsidiary, Cortigent, to become an independent public company.
Key Highlights
- SLIM-1 Phase 1 clinical trial for NPM-139 on track for mid-2026 initiation.
- Top-line SLIM-1 results are anticipated by the end of 2026.
- $28 million in cash, equivalents, and commitments fund operations through H1 2027.
- Net loss for Q1 2026 was $6.8 million, compared to $6.3 million in Q1 2025.
- Research and development expense increased to $4.4 million in Q1 2026.
- Raised $30.2 million in gross proceeds over the last 12 months.
- Cortigent Inc. filed an S-1 amendment, exploring spin-off or IPO.
Price Impact
More from VANI